This greater prevalence could be, at least in part, due to the use of macrolides in the chemoprevention of Mycobacterium avium complex (MAC) infection in severely immunocompromised HIV patients (CD4 counts <100). The gene discussed is CD4; the disease is Mycobacterium avium complex disease.